BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory syncytial virus (RSV) preventive developed by French drugmaker Sanofi and ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

RSV compared to those who did not get BEYFORTUS, per new post-hoc analysis MORRISTOWN, N.J., July 22, 2025 /PRNewswire/ -- The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

About Beyfortus clinical trial data Prior to the real-world studies, BEYFORTUS was evaluated in two pivotal trials.

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...